BACKGROUND: Neurological side effects of antipsychotic agents limit the use of these drugs, and development of newer antipsychotic agents has been focused on a reduced risk of @entity21 ( @entity21 ) as well as effective symptom control. METHODS: A qualitative analysis of @entity21 was performed using Extrapyramidal Symptom Rating Scale (ESRS) data from 11 double-blind @entity1090 trials. An ESRS factor analysis and maximum changes in ESRS scores were compared for the @entity1090 , @entity1767 , and placebo groups. RESULTS: The factor analysis revealed five factors. Between-group comparisons showed no differences between placebo and 1 to 2 mg/day- @entity1090 groups. @entity304 , @entity400 , @entity2146 , and @entity4164 were more likely to occur with @entity1767 than with placebo or @entity1090 at 1 to 6 mg/day. Similar results were noted by maximum changes in ESRS scores. At @entity1090 doses of more than 8 mg/day, acute @entity21 severity lay between that of the placebo and @entity1767 groups. The severity of @entity910 was greater in @entity1 receiving placebo than in those receiving either active treatment. CONCLUSIONS: As the results described above were derived from a post hoc analysis of an existing database, conclusions must remain tentative. To provide more definitive answers, @entity21 assessments in future studies should be refined to more accurately predict the type of @entity21 expected with a given agent in clinical practice.

A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a XXXX database.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity304 :: ('MESH:D010302', 'Disease') :: ['Parkinsonism'] @entity910 :: ('MESH:D004409', 'Disease') :: ['tardive dyskinesia'] @entity4164 :: ('MESH:D012798', 'Disease') :: ['sialorrhea'] @entity400 :: ('MESH:D014202', 'Disease') :: ['tremor'] @entity2146 :: ('MESH:D011595', 'Disease') :: ['akathisia'] @entity1767 :: ('MESH:D006220', 'Chemical') :: ['haloperidol'] @entity21 :: ('MESH:D001480', 'Disease') :: ['extrapyramidal symptoms', 'EPS'] @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone']
@entity1090 :: (MESH:D018967,Chemical) :: ['risperidone']
